In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices

被引:123
作者
Alexis, F [1 ]
Venkatraman, SS [1 ]
Rath, SK [1 ]
Boey, F [1 ]
机构
[1] Nanyang Technol Univ, Sch Mat Engn, Singapore 639798, Singapore
关键词
biodegradable stent; paclitaxel; rapamycin; lidocaine; restenosis;
D O I
10.1016/j.jconrel.2004.04.011
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We have studied the in vitro release kinetics of two important antirestenosis drugs from biodegradable stent matrices. A helical stent incorporating drugs was exposed to buffer, and both degradation-controlled and diffusion-controlled drug releases were observed. New methods for in vitro drug release for both paclitaxel and rapamycin have been developed. The release profile shows a slow diffusion-controlled phase, followed by a more rapid degradation-controlled region. In the early part of the drug release, no burst effect is observed for either drug. This might be significant for paclitaxel administration, where cardiotoxicity has been sometimes of concern. By suitable polymer/drug formulations, it is possible to develop controlled release stent matrices that can exhibit a variety of release profiles. These release profiles may have relevance to antirestenotic effects and to local or systemic toxic effects. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:67 / 74
页数:8
相关论文
共 36 条
[1]  
ALEXIS F, 2004, J CONTROL RELASE MAR
[2]  
Am. Soc. Health Syst. Pharm, 1989, AHFS DRUG INF, P1075
[3]  
BAKER R, 1987, CONTROLLED RELEASE B, P39
[4]   Rapamycin (sirolimus) inhibits heart cell growth in vitro [J].
Burton, PBJ ;
Yacoub, MH ;
Barton, PJR .
PEDIATRIC CARDIOLOGY, 1998, 19 (06) :468-470
[5]   Sirolimus-eluting stent for treatment of complex in-stent restenosis - The first clinical experience [J].
Degertekin, M ;
Regar, E ;
Tanabe, K ;
Smits, PC ;
van der Giessen, WJ ;
Carlier, SG ;
de Feyter, P ;
Vos, J ;
Foley, DP ;
Ligthart, JMR ;
Popma, JJ ;
Serruys, PW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (02) :184-189
[6]   Neointimal thickening after stent delivery of paclitaxel: Change in composition and arrest of growth over six months [J].
Drachman, DE ;
Edelman, ER ;
Seifert, P ;
Groothuis, AR ;
Bornstein, DA ;
Kamath, KR ;
Palasis, M ;
Yang, DC ;
Nott, SH ;
Rogers, C .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (07) :2325-2332
[7]   Local drug delivery via a coronary stent with programmable release pharmacokinetics [J].
Finkelstein, A ;
McClean, D ;
Kar, S ;
Takizawa, K ;
Varghese, K ;
Baek, N ;
Park, K ;
Fishbein, MC ;
Makkar, R ;
Litvack, F ;
Eigler, NL .
CIRCULATION, 2003, 107 (05) :777-784
[8]  
FISHBEIN I, 2000, BIOMATERIALS BIOENGI, P313
[9]   HYDROLYTIC DEGRADATION OF DEVICES BASED ON POLY(DL-LACTIC ACID) SIZE-DEPENDENCE [J].
GRIZZI, I ;
GARREAU, H ;
LI, S ;
VERT, M .
BIOMATERIALS, 1995, 16 (04) :305-311
[10]  
Heldman AW, 1999, CATHETER CARDIO INTE, V47, P107